Are GLP-1 prices going down?

Both directions are happening at once, which is why a single answer is misleading. Compounded telehealth medication prices have fallen — one provider cut its advertised semaglutide from $99 to $60 and its tirzepatide from $199 to $90 during August 2026. Meanwhile the cheapest approved self-pay tier is scheduled to rise: NovoCare states the tier covering the 4 mg Wegovy tablet goes from $149 to $199 a month after 31 August 2026. Manufacturer list prices are also due to fall to $675 on 1 January 2027, which mostly affects people paying a percentage of list rather than a flat price.

When will GLP-1 prices go down?

One dated, publicly announced reduction exists: Novo Nordisk stated on 24 February 2026 that the US list price of Wegovy, Ozempic and Rybelsus falls to $675 from 1 January 2027, and said the change does not affect direct-to-patient self-pay prices. Everything else is speculation, and we do not publish forecasts of prices.

How far back does this price history go?

It starts on 25 July 2026, because that is when this site began reading these pages. We do not hold a price for a date before we read it, and we do not estimate one. A chart running back several years would be worth more to us and less to you.

Can I reuse this data?

Yes. The series is published as JSON under a CC BY 4.0 licence, with a suggested citation included in the file. If you use it, a link back is the attribution.

Cost & coverage

What GLP-1 prices have done, and what they are about to do

Evidence-sourced

Written and fact-checked to our published editorial standards.Last updated 2026-08-21. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Strong

Prices in this category are moving in both directions at once, which is why “are they going down” has no single answer. Compounded telehealth medication has got cheaper — one provider cut its advertised semaglutide from $99 to $60 and its tirzepatide from $199 to $90 inside a fortnight. The cheapest approved self-pay tier is going the other way: NovoCare states the 4 mg Wegovy tablet tier rises from $149 to $199 a month after 31 August 2026.

Key takeaways

1 announced change has not taken effect yet — that is the row worth acting on.
Manufacturer list prices fall to $675 on 1 January 2027, which matters only if you pay a percentage of list rather than a flat figure.
This series began on 25 July 2026 and is 27 days old. Nothing in it is back-filled.
The data is published as JSON under CC BY 4.0, and a link is the attribution.

Important limitation: A price series is the easiest thing on a site like this to fabricate, because nobody can check what a telehealth company charged last March. So this one holds no figure for a date before we read it, which makes it short. It gets useful by continuing, not by being padded.

Next action: If your question is what to pay today rather than what it did last month, that is the route-by-route comparison, which prices every way of paying side by side.

Primary sources: NovoCare, Novo Nordisk, Eli Lilly and Company

General education, not medical or financial advice. Published prices change without notice; the seller's own page is the authority.

Announced, not yet in effect

These are the rows a reader can still act on, which is why they sit above the record rather than inside it.

Wegovy tablets, self-pay — $199/month from 2026-08-31

NovoCare states the 4 mg tier rises to this after 31 August 2026. Not yet in force at the time of writing.

NovoCare self-pay pricing, read 2026-08-13

What has actually moved

2 of the series we track have more than one reading, which is the only way to show movement rather than assert it:

Wegovy tablets, self-pay: $149 on 2026-08-13 to $199 on 2026-08-31 (announced, not yet in force).
Mochi Health, compounded semaglutide: $138 on 2026-08-11 to $139 on 2026-08-21.

Every observation in the series, newest first. “We read it” means the figure was on the seller’s own page on that date. “Seller announced” means it was publicly stated along with the date it applies from. There is no third category, and no figure is estimated.
Date	What was priced	Monthly	Basis, and where it came from
2026-08-31	Wegovy tablets, self-payNovoCare states the 4 mg tier rises to this after 31 August 2026. Not yet in force at the time of writing.	$199	Seller announcedNovoCare self-pay pricing, read 2026-08-13
2026-08-21	Foundayo, self-payThe 0.8 mg dose; $199 at 2.5 mg and $299 above that. We had recorded no self-pay price for this product until this date — see the correction of the same day.	$149	We read itFoundayo (Eli Lilly) coverage and savings page
2026-08-21	Mochi Health, compounded semaglutideMedication moved to $60, advertised as a reduction from $99.	$139	We read itOur 21 August re-read of joinmochi.com
2026-08-21	Mochi Health, compounded tirzepatide$79 membership plus $90 medication, advertised as a reduction from $199. This option existed before this date; our cost model had never carried it.	$169	We read itOur 21 August re-read of joinmochi.com
2026-08-13	Wegovy tablets, self-payThe 1.5 mg and 4 mg tiers.	$149	We read itNovoCare self-pay pricing
2026-08-11	Mochi Health, compounded semaglutide$79 membership plus $59 medication — our arithmetic on the provider's two published figures.	$138	We read itOur 11 August sweep of joinmochi.com
2026-08-11	Success by SesameMedication included. This site had previously recorded an optional subscription from $59 a month, which is a different thing being priced rather than the same thing changing.	$249	We read itOur 11 August sweep of sesamecare.com
2026-08-11	Calibrate, The Metabolic ResetProgramme fee only, on a three-month minimum. Medication is billed to the member's own insurance and no cash price is published.	$199	We read itOur 11 August sweep of joincalibrate.com
2026-07-25	Zepbound KwikPen, self-payLowest dose. Higher doses were published at $399 and $449.	$299	We read itEli Lilly, Zepbound coverage and savings page

A price series is the easiest thing to fake and the hardest to check. This one holds no figure for a date before we read it, which is why it is short.

Use the data

The series is published as JSON at a stable address, containing the same observations as the table above with the source attached to each. It is licensed CC BY 4.0, so you may use it commercially and republish it, provided you attribute it. A link back is the attribution.

GLP-1 Healthcare, “Published GLP-1 prices, dated”. https://www.glp1.healthcare/glp-1/cost/price-tracker

The export deliberately carries nothing the page does not show. An export richer than the page would be unverifiable by exactly the people most likely to check it.

Why this is separate from the price comparison

This page answers a question about time. What something costs today, across every way of paying for it, is a different question with a different answer, and it has its own page: every route priced side by side, with membership fees added in. Keeping the two apart is deliberate — a tracker that also tried to be a comparison would be worse at both, and the two would compete with each other for the same readers.

Common questions

Are GLP-1 prices going down?: Both directions are happening at once, which is why a single answer is misleading. Compounded telehealth medication prices have fallen — one provider cut its advertised semaglutide from $99 to $60 and its tirzepatide from $199 to $90 during August 2026. Meanwhile the cheapest approved self-pay tier is scheduled to rise: NovoCare states the tier covering the 4 mg Wegovy tablet goes from $149 to $199 a month after 31 August 2026. Manufacturer list prices are also due to fall to $675 on 1 January 2027, which mostly affects people paying a percentage of list rather than a flat price.
When will GLP-1 prices go down?: One dated, publicly announced reduction exists: Novo Nordisk stated on 24 February 2026 that the US list price of Wegovy, Ozempic and Rybelsus falls to $675 from 1 January 2027, and said the change does not affect direct-to-patient self-pay prices. Everything else is speculation, and we do not publish forecasts of prices.
How far back does this price history go?: It starts on 25 July 2026, because that is when this site began reading these pages. We do not hold a price for a date before we read it, and we do not estimate one. A chart running back several years would be worth more to us and less to you.
Can I reuse this data?: Yes. The series is published as JSON under a CC BY 4.0 licence, with a suggested citation included in the file. If you use it, a link back is the attribution.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

NovoCare self-pay pricingNovoCare, Novo NordiskSupports: The Wegovy tablet self-pay tiers and the stated rise for the 4 mg dose after 31 August 2026.
Foundayo coverage and savingsEli Lilly and CompanySupports: Foundayo self-pay pricing by dose, first recorded here on 21 August 2026.
Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status of every product priced in this series.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.